AI Engines For more Details: Perplexity Kagi Labs You
Hyperlipidemia: Clofibrate is primarily prescribed to treat hyperlipidemia, a condition characterized by high levels of fats (lipids) in the blood, including triglycerides and cholesterol. Clofibrate works by increasing the breakdown of triglycerides in the liver and reducing the production of very low-density lipoprotein (VLDL), a type of lipoprotein that carries triglycerides. By lowering triglyceride levels and, to a lesser extent, cholesterol levels, clofibrate helps reduce the risk of cardiovascular diseases such as heart attack and stroke.
Mixed Hyperlipidemia: Clofibrate may be used in the treatment of mixed hyperlipidemia, where there are elevated levels of both triglycerides and cholesterol in the blood. By targeting triglycerides and cholesterol simultaneously, clofibrate can help improve the overall lipid profile and reduce the risk of cardiovascular events in individuals with mixed hyperlipidemia.
Coronary Heart Disease (CHD) Prevention: Lowering triglyceride levels with clofibrate has been shown to be associated with a reduction in the risk of coronary heart disease (CHD) events, such as heart attack and angina, particularly in individuals with elevated triglyceride levels. However, the overall cardiovascular benefits of clofibrate therapy have been debated, and its use has declined over time with the availability of more effective lipid-lowering medications such as statins.
Post-Myocardial Infarction (Heart Attack) Therapy: Clofibrate has been studied in the past as a potential therapy for reducing cardiovascular events and mortality in individuals who have had a myocardial infarction (heart attack). Some clinical trials suggested a potential benefit of clofibrate in reducing recurrent heart attacks and deaths from cardiovascular causes. However, subsequent research and meta-analyses have raised concerns about the overall efficacy and safety of clofibrate in this population.
Off-Label Uses: In addition to its lipid-lowering effects, clofibrate has been investigated for potential therapeutic benefits in other medical conditions, such as diabetes mellitus and metabolic syndrome. Some studies have suggested that clofibrate may have beneficial effects on insulin sensitivity and glucose metabolism, although its use in these conditions is not well-established and is not commonly recommended.
Side Effects and Safety Concerns: Clofibrate therapy may be associated with certain side effects, including gastrointestinal symptoms (such as nausea, vomiting, and diarrhea), liver function abnormalities, gallstones, and muscle weakness or pain. Additionally, clofibrate has been associated with an increased risk of certain adverse events, including rhabdomyolysis (a severe muscle injury), pancreatitis, and an elevated risk of cancer, particularly gallbladder cancer.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.5 | 0.5 | |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.3 | -0.5 |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.1 | -0.1 | |
| Allergy to milk products | 0.1 | 0.3 | -2 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 0.1 | 0.3 | -2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0 | |
| Ankylosing spondylitis | 0.5 | 0.1 | 4 |
| Anorexia Nervosa | 0.3 | 0.3 | 0 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 0.3 | -0.3 | |
| Atherosclerosis | 0 | 0.6 | 0 |
| Atrial fibrillation | 0.4 | 0.3 | 0.33 |
| Autism | 1.1 | 0.6 | 0.83 |
| Bipolar Disorder | 0.4 | 0.2 | 1 |
| Brain Trauma | 0.3 | -0.3 | |
| Carcinoma | 0.4 | 0.4 | 0 |
| Celiac Disease | 0.1 | 0.4 | -3 |
| Cerebral Palsy | 0.3 | -0.3 | |
| Chronic Fatigue Syndrome | 0.8 | 0.6 | 0.33 |
| Chronic Kidney Disease | 0.3 | 0.2 | 0.5 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | -0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.2 | 0.5 |
| Colorectal Cancer | 0.6 | 0.6 | |
| Constipation | 0.1 | 0.2 | -1 |
| Coronary artery disease | 0 | 0 | |
| COVID-19 | 0.5 | 0.9 | -0.8 |
| Crohn's Disease | 0.6 | 0.6 | 0 |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.2 | -0.2 | |
| Depression | 1.9 | 0.6 | 2.17 |
| Endometriosis | 0.3 | 0 | 0 |
| Epilepsy | 0.1 | 0.3 | -2 |
| Fibromyalgia | 0.5 | 0.1 | 4 |
| Functional constipation / chronic idiopathic constipation | 0.8 | 0.3 | 1.67 |
| gallstone disease (gsd) | 0.3 | 0.2 | 0.5 |
| Generalized anxiety disorder | 0.1 | -0.1 | |
| Graves' disease | 0.3 | 0.2 | 0.5 |
| Halitosis | 0.1 | 0.1 | |
| Hashimoto's thyroiditis | 0.3 | 0.1 | 2 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.3 | 0.3 | |
| hyperglycemia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.4 | 0.3 | 0.33 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.1 | -0.1 | |
| Inflammatory Bowel Disease | 0.1 | 1.3 | -12 |
| Insomnia | 0.1 | 0.3 | -2 |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 0.5 | 0.5 | 0 |
| Liver Cirrhosis | 0.6 | 0.3 | 1 |
| Long COVID | 1 | 0.8 | 0.25 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 0 | 0 | |
| ME/CFS with IBS | 0.5 | 0.1 | 4 |
| ME/CFS without IBS | 0.1 | 0.6 | -5 |
| Metabolic Syndrome | 0.6 | 0.6 | 0 |
| Mood Disorders | 1.9 | 0.6 | 2.17 |
| Multiple Sclerosis | 0.3 | 1.1 | -2.67 |
| Multiple system atrophy (MSA) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | -0.1 | |
| Obesity | 0.6 | 0.4 | 0.5 |
| obsessive-compulsive disorder | 0.4 | 0.1 | 3 |
| Osteoarthritis | 0.1 | 0 | 0 |
| Osteoporosis | 0.1 | 0.1 | 0 |
| Parkinson's Disease | 0.3 | 0.6 | -1 |
| Polycystic ovary syndrome | 0.4 | 0.3 | 0.33 |
| Premenstrual dysphoric disorder | 0.3 | -0.3 | |
| Psoriasis | 0 | 1 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.3 | 1 |
| Rosacea | 0 | 0.2 | 0 |
| Schizophrenia | 0.4 | 0.2 | 1 |
| scoliosis | 0 | 0 | |
| Sjögren syndrome | 0.3 | 0.3 | 0 |
| Sleep Apnea | 0 | 0.3 | 0 |
| Stress / posttraumatic stress disorder | 0.5 | 0.3 | 0.67 |
| Systemic Lupus Erythematosus | 0.3 | 0.2 | 0.5 |
| Tic Disorder | 0 | 0 | |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.1 | 0.2 | -1 |
| Type 2 Diabetes | 0.6 | 0.7 | -0.17 |
| Ulcerative colitis | 0.1 | 0.5 | -4 |
| Unhealthy Ageing | 0.6 | 0.2 | 2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.